Researchers noted that after a median follow-up of 3.7 years, canakinumab recipients had lower rates of cancer mortality (HR 0.49, p = 0.0009), lung cancer incidence (HR 0.61, p = 0.034), lung cancer mortality (HR 0.23, p = 0.0002) compared to those on placebo, along with reductions in C-reactive protein (CRP) and IL-6 levels. This evidence concerns the gene IL6 and lung cancer.